美国自动化细胞处理/封闭式细胞治疗处理系统市场规模、份额和趋势分析报告：按工作流程、类型、规模和细分市场进行预测，2025-2030 年

美国自动化细胞处理和封闭式细胞治疗处理系统市场的成长和趋势

Grand View Research, Inc.最新报告显示，到2030年，美国自动化细胞处理和封闭式细胞治疗处理系统市场规模将达到18.7亿美元，2025年至2030年复合年增长率为19.41%。 。

对再生医学和细胞疗法的日益关注、自动化系统相对于手动处理的操作优势以及广泛不断的技术进步是推动市场成长的一些关键因素。

人们对再生医学的认识不断提高，预计将推动对细胞治疗的需求，并最终推动对自动化和封闭式细胞治疗处理系统的需求，从而推动市场成长。例如，2024年9月，Arsenal Biosciences完成了3.25亿美元的C轮资金筹措并获得超额认购。借助这笔资金筹措，该公司将推进针对固体癌的CAR T 细胞疗法。现有投资者支持该公司，包括帕剋癌症免疫治疗研究所、Softbank CorporationVision Fund 2、百时美施贵宝、Westlake Village BioPartners、Kleiner Perkins、Byers Capital 和 Hitachi Ventures。

我强调，COVID-19 大流行凸显了细胞疗法对可扩展和弹性製造的迫切需求，以及随着治疗需求的增加，自动化系统在确保一致和可重复的品质流程方面的作用。自动化可以帮助面临劳动力限制的公司维持生产标准，这使其对于当前和未来的治疗需求至关重要。自动化系统的日益普及凸显了该技术在建立可靠、高品质的细胞治疗製造方面的作用。

儘管取得了这些进展，疫情也对美国自动化细胞处理和封闭式细胞治疗处理系统市场产生了负面影响。全球供应链中断导致生产和分销延迟，限制了维持基本设备和材料稳定供应线的能力。此外，资源用于 COVID-19 治疗，暂停了某些细胞治疗计划并减缓了创新。因此，细胞治疗药物的一些开发和生产计划被延长，在短期内影响了研究和商业化。

此外，大量正在进行的临床试验以及政府机构为加速细胞疗法研究和开发而不断增加的支持是美国市场的主要驱动因素。例如，2024 年 10 月，纽约州在长岛推出了雄心勃勃、耗资 4.3 亿美元的生物起源公园计划。凭藉 1.5 亿美元的国家投资以及与当地组织的合作，该设施旨在成为细胞和基因治疗创新的领先中心。这些努力预计将加速细胞疗法製造自动化系统的采用。

然而，这项技术相对较新，需要对过程有深入的了解和明确的策略才能达到预期的结果。此外，有必要为系统提供足够的资料来理解该过程。完成此步骤后，您需要了解自动化的流程控制。整个过程需要熟练的人力和高端设备。缺乏可以实现细胞治疗过程自动化的兼容硬体平台。由于大量的资本需求，预计市场成长将受到一定程度的阻碍。

美国自动化细胞处理/闭式细胞治疗处理系统市场报告亮点

• 根据工作流程，预计分离细分市场将在 2024 年以 31.10% 的最高收益占有率主导市场，并在预测期内以最快的复合年增长率成长。这一巨大份额是由于治疗应用对有效细胞分离和精製技术的需求不断增加。
• 从类型来看，非干细胞治疗领域占据市场主导地位，2024年市占率为61.84%。这是由于非干细胞治疗应用的产品推出增加。
• 从规模来看，预商用/研发规模细分市场占比最大，2024年达74.96%。这些系统主要用于早期研究、製程开发和临床试验。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 市场变数、趋势与范围

• 市场体系展望
  • 母市场展望
  • 相关/辅助市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 产业分析工具
  • 波特五力分析
  • PESTEL分析
  • COVID-19 影响分析

第四章美国自动化细胞处理/闭孔细胞治疗处理系统市场：依工作流程进行业务分析

• 工作流程细分仪表板
• 美国自动化细胞处理/封闭式细胞治疗处理系统市场工作流程波动分析
• 2018-2030年美国自动化细胞处理/封闭式细胞治疗处理系统市场规模与趋势分析（依工作流程）
• 分离
• 扩张
• 血浆分离术
• 填充完成
• 冷冻保存
• 其他的

第五章美国自动化细胞处理/闭式细胞治疗处理系统市场：按类型分类的业务分析

• 类型细分仪表板
• 美国自动化细胞处理/封闭式细胞治疗处理系统市场类型及波动分析
• 2018-2030年美国自动化细胞处理/封闭式细胞治疗处理系统市场规模及类型趋势分析
• 干细胞疗法
• 非干细胞疗法

第六章美国自动化细胞处理/闭式细胞治疗处理系统市场：按规模进行的业务分析

• 刻度细分仪表板
• 美国自动化细胞处理/封闭式细胞治疗处理系统市场规模波动分析
• 2018-2030年美国自动化细胞处理/封闭式细胞治疗处理系统市场规模及趋势分析（依规模）
• 预商业/研发规模
• 商业规模

第七章 竞争格局

• 参与企业
• 策略规划
• 2024 年企业市场分析
• 参与企业概况
  • Thermo Fisher Scientific Inc.
  • Lonza
  • MiltenyiBiotec
  • Danaher
  • Sartorius AG
  • Fresenus
  • MaxCyte, Inc.
  • ThermoGenesis Holdings, Inc.
  • Terumo Corporation
  • Cellares Inc.

U.S. Automated And Closed Cell Therapy Processing Systems Market Growth & Trends:

The U.S. automated and closed cell therapy processing systems market size is anticipated to reach USD 1.87 billion by 2030, growing at a CAGR of 19.41% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing emphasis on regenerative medicines and cell therapies, operational superiority of automated systems over manual processing, and extensively increasing technological advancements are some of the major factors driving the growth of the market.

The growing awareness about regenerative medicine is expected to drive the demand for cell therapies, eventually driving the need for automated and closed-cell therapy processing systems and fueling market growth. For instance, in September 2024, Arsenal Biosciences completed a USD 325 million Series C funding round, which was oversubscribed. This funding will help the company advance its CAR T-cell therapies for solid tumors. Existing investors supported the company, including the Parker Institute for Cancer Immunotherapy, SoftBank Vision Fund 2, Bristol-Myers Squibb, Westlake Village BioPartners, Kleiner Perkins, Byers Capital, and Hitachi Ventures.

The COVID-19 pandemic underscored the critical need for scalable, resilient manufacturing in cell therapies, emphasizing automated systems' role in ensuring consistent, repeatable quality processes amid rising demand for therapeutics. Automation helps companies maintain production standards when faced with workforce constraints, making it essential for current and anticipated therapeutic needs. The increased adoption of automated systems highlighted the technology's role in establishing reliable, high-quality cell therapy manufacturing.

Despite these advancements, the pandemic also negatively affected the U.S. automated and closed-cell therapy processing systems market. Global supply chain disruptions caused delays in production and distribution, limiting the ability to maintain steady supply lines for essential equipment and materials. Resources were also redirected toward COVID-19 treatments, pausing certain cell therapy projects and slowing innovation. As a result, some development and manufacturing timelines for cell therapies were extended, impacting both research and commercialization efforts in the short term.

Moreover, many ongoing clinical trials coupled with the increasing support from government bodies to accelerate the R&D of cell therapy are major drivers of the U.S. market. For instance, in October 2024, New York launched the ambitious BioGenesis Park project on Long Island, supported by a USD 430 million investment. This facility aims to be a major hub for cell and gene therapy innovation, driven by a USD 150 million state investment and partnerships with local organizations. Such initiatives are expected to boost the adoption of automated systems for cell therapy manufacturing.

However, as the technology is relatively new, it requires a deep understanding of the process and a well-articulated strategy to achieve desired outcomes. Furthermore, providing enough data for the system to understand the process is necessary. After this step, one needs to understand process control for automation. This overall progression requires skilled manpower and high-end devices. There is a shortage of compatible hardware platforms that can help achieve automation in cell therapy processes. The need for extensive capital is expected to impede market growth to a certain extent.

U.S. Automated And Closed Cell Therapy Processing Systems Market Report Highlights:

• Based on workflow, the separation segment dominated the market with the highest revenue share of 31.10% in 2024 and is anticipated to grow at the fastest CAGR during the forecast period. The large share is attributed to the increasing demand for efficient cell isolation and purification techniques in therapeutic applications
• Based on the type, the non-stem cell therapy segment dominated the market in 2024 with a share of 61.84%. This can be attributed to increasing product launches for non-stem cell therapy applications
• Based on scale, the pre-commercial/R&D scale segment held the largest share of 74.96% in 2024. These systems are used primarily in early-stage research, process development, and clinical trials

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Workflow Segment
  • 1.2.2. Type Segment
  • 1.2.3. Scale Segment
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing emphasis on regenerative medicines and cell therapies
    • 3.2.1.2. Operational superiority of automated systems over manual processing
    • 3.2.1.3. Extensively increasing technological advancements
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Complications associated with cell processing systems
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Automated and Closed Cell Therapy Processing Systems Market: Workflow Business Analysis

• 4.1. Workflow Segment Dashboard
• 4.2. U.S. Automated and Closed Cell Therapy Processing Systems Market Workflow Movement Analysis
• 4.3. U.S. Automated and Closed Cell Therapy Processing Systems Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
• 4.4. Separation
  • 4.4.1. Separation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Expansion
  • 4.5.1. Expansion Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Apheresis
  • 4.6.1. Apheresis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Fill-finish
  • 4.7.1. Fill-finish Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Cryopreservation
  • 4.8.1. Cryopreservation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Automated and Closed Cell Therapy Processing Systems Market: Type Business Analysis

• 5.1. Type Segment Dashboard
• 5.2. U.S. Automated and Closed Cell Therapy Processing Systems Market Type, Movement Analysis
• 5.3. U.S. Automated and Closed Cell Therapy Processing Systems Market Size & Trend Analysis by Type, 2018 to 2030 (USD Million)
• 5.4. Stem Cell Therapy
  • 5.4.1. Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Non-stem Cell Therapy
  • 5.5.1. Non-stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Automated and Closed Cell Therapy Processing Systems Market: Scale Business Analysis

• 6.1. Scale Segment Dashboard
• 6.2. U.S. Automated and Closed Cell Therapy Processing Systems Market Scale Movement Analysis
• 6.3. U.S. Automated and Closed Cell Therapy Processing Systems Market Size & Trend Analysis, by Scale, 2018 to 2030 (USD Million)
• 6.4. Pre-commercial/ R&D Scale
  • 6.4.1. Pre-commercial/ R&D Scale Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Commercial Scale
  • 6.5.1. Commercial Scale Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Categorization
• 7.2. Strategy Mapping
• 7.3. Company Market Position Analysis, 2024
• 7.4. Participant's Overview
  • 7.4.1. Thermo Fisher Scientific Inc.
    • 7.4.1.1. Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. Lonza
    • 7.4.2.1. Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. MiltenyiBiotec
    • 7.4.3.1. Overview
    • 7.4.3.2. Product Benchmarking
    • 7.4.3.3. Strategic Initiatives
  • 7.4.4. Danaher
    • 7.4.4.1. Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. Sartorius AG
    • 7.4.5.1. Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. Fresenus
    • 7.4.6.1. Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. MaxCyte, Inc.
    • 7.4.7.1. Overview
    • 7.4.7.2. Product Benchmarking
    • 7.4.7.3. Strategic Initiatives
  • 7.4.8. ThermoGenesis Holdings, Inc.
    • 7.4.8.1. Overview
    • 7.4.8.2. Product Benchmarking
    • 7.4.8.3. Strategic Initiatives
  • 7.4.9. Terumo Corporation
    • 7.4.9.1. Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Cellares Inc.
    • 7.4.10.1. Overview
    • 7.4.10.2. Product Benchmarking
    • 7.4.10.3. Strategic Initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 U.S. Automated and Closed Cell Therapy Processing Systems market, by workflow, 2018 - 2030 (USD million)
• Table 4 U.S. Automated and Closed Cell Therapy Processing Systems market, by type, 2018 - 2030 (USD million)
• Table 5 U.S. Automated and Closed Cell Therapy Processing Systems market, by Scale, 2018 - 2030 (USD million)
• Table 6 U.S. Automated and Closed Cell Therapy Processing Systems market, by region, 2018 - 2030 (USD million)
• Table 7 Participant's overview
• Table 8 Financial performance

List of Figures

• Fig. 1 U.S. Automated and Closed Cell Therapy Processing Systems Market Segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Market formulation & validation
• Fig. 7 Market outlook
• Fig. 8 Segment snapshot
• Fig. 9 Competitive landscape snapshot
• Fig. 10 Parent market outlook
• Fig. 11 U.S. Automated and Closed Cell Therapy Processing Systems Market Driver Analysis
• Fig. 12 U.S. Automated and Closed Cell Therapy Processing Systems Market Restraint Analysis
• Fig. 13 Porter's analysis
• Fig. 14 PESTEL analysis
• Fig. 15 U.S. Automated and Closed Cell Therapy Processing Systems market: Workflow outlook and key takeaways
• Fig. 16 U.S. Automated and Closed Cell Therapy Processing Systems market: Workflow market share analysis, 2023 - 2030
• Fig. 17 Separation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 Expansion market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Apheresis market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Fill-finish flasks market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Cryopreservation permeable membrane flasks market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 U.S. Automated and Closed Cell Therapy Processing Systems market: Type outlook and key takeaways
• Fig. 24 U.S. Automated and Closed Cell Therapy Processing Systems market: Type market share analysis, 2023 - 2030
• Fig. 25 Stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Non-stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 U.S. Automated and Closed Cell Therapy Processing Systems market: Scale outlook and key takeaways
• Fig. 28 U.S. Automated and Closed Cell Therapy Processing Systems market: Scale market share analysis, 2024 - 2030
• Fig. 29 Pre-commercial/ R&D scale market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Commerical scale market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Key company categorization
• Fig. 32 Company market positioning
• Fig. 33 Market participant categorization
• Fig. 34 Strategy framework